Together, these findings provide conclusive evidence for the crucial involvement of tumor Tet2 and Stat5a in VC-mediated vascular normalizing effects and the combinational efficiency of VC and anti-PD-L1 therapy in liver cancer. This evidence concerns the gene STAT5A and neoplasm.